Skip to main content



Local Cdiff information for Nebraska

Nebraska

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Nebraska.



Local Cdiff information for Nebraska

Nebraska

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Nebraska.

Providers

Regulation

C. diff Infections

Total Reported Cases: 452
Hospital Onset: 452
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.83
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: Yes
Data Publicly Available: No
Data Validated: No
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: 173 NAC 1
STATUTE >

State Contact

Maureen R. Tierney, M.D., MSc.
Healthcare Associated Infections Coordinator
Nebraska Dept. of Health & Human Services
Division of Public Health
301 Centennial Mall
Lincoln, 68509
(402) 471-6549
(402) 471-3601
EMAIL MAUREEN R. TIERNEY, M.D., MSC. >

CLINICAL TRIALS

ROAR

Official Title: REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study
Trial No. NCT05835219
Type: Observational
Recruitment: Recruiting
Sponsor: Ferring Pharmaceuticals
Contact: Global Clinical Compliance
833-548-1402
EMAIL
Gender: All
Age: 18 Years and older

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

LMN-201

Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Trial No. NCT05330182
Type: Interventional
Recruitment: Recruiting
Sponsor: Lumen Bioscience, Inc.
Contact: Carl Mason, MD
EMAIL >
Gender: All
Age: 18 Years and older